*Updated : On March 30, 2020, the Ontario government launched a 24-hour consultation on its proposal to change the effective date of the regulatory amendments for private label products from July 1, 2020 to April 1, 2020. The government’s rationale is that the availability of private label products will reduce the risk of drug shortages in the context of the COVID-19 pandemic.
Link to the consultation :https://www.ontariocanada.com/registry/view.do?postingId=32067&language=en
—
On December 16, 2019, the Ontario Ministry of Health announced the following regulatory amendments:
- Remove the financial cap on Ordinary Commercial Term (OCT) benefits, effective as of January 1, 2020
- Allow Private Label Products to be designated as listed drug products or as interchangeable products on the Ontario Drug Benefit Formulary/ Comparative Drug Index as of July 1, 2020.
Read the full notice here: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/exec_office_20191216_3.pdf